ImmVira Group Company, a biotechnology company, has signed a clinical collaboration and exclusive license agreement with China-based Shanghai Pharmaceuticals Holding Co Ltd, it was reported on Thursday.
The contract has been signed for ImmVira's MVR-T3011 intratumoral oncolytic virus program for the commercialisation of immunotherapies to treat solid malignant tumours.
According to the terms of the contract, ImmVira will receive from Shanghai Pharma an upfront payment and contingent milestone payments worth RMB1.15bn, and royalty payments of up to 12% of net revenues if Shanghai Pharma successfully commercialises a therapy from the partnership.
Eli Lilly announces Q1 2026 dividend
Amgen announces Q4 2025 dividend
Bavarian Nordic secures new EU contract for up to 8 million smallpox and mpox vaccine doses
Thermo Fisher Scientific to acquire Clario Holdings, expanding clinical data capabilities
Nanoform and Revio Therapeutics partner to develop long-acting hydrogel therapy for glioma
Cumberland Pharmaceuticals adds FDA-approved oral capsule for H. pylori to commercial portfolio
IP Group positions for future royalties following Pfizer's USD7.3bn acquisition of Metsera
AstraZeneca strikes landmark drug pricing deal with US Government